Together with the R&D center in Zofingen, it will offer chemical process R&D and analytical development services for Siegfried's global drug substances network. With workspaces for over 100 specialists and 40 new jobs created, the R&D center strengthens Siegfried’s development capabilities in phase II and III supporting the company's Evolve+ strategy, the company said.

Marcel Imwinkelried, CEO of Siegfried, commented: “The new R&D Center in Evionnaz significantly enhances our Drug Substances network and demonstrates our unwavering commitment to providing cutting-edge research and development capabilities for our customers. It will be a key element in driving development excellence as part of our Evolve+ strategy and represents another pivotal step in strengthening our position among the top providers in the CDMO sector."